膠原病リウマチ疾患ごと– category –
-
JAK阻害薬の安全性をTNFα阻害薬と比較したメタアナリシス(JAMA network open vol. 8,9 e2531204. 2 Sep. 2025)
Comparative Safety of JAK Inhibitors vs TNF Antagonists in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis JAMA network open&nbs... -
RECITAL trial
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-b... -
SLS2 Trial
Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, para... -
SLS1 Trial 追加解析
Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease Donald P. Tashkin, Robert Elashoff, Philip J. Clements, ... -
SLS1 Trial
Cyclophosphamide versus Placebo in Scleroderma Lung Disease Donald P. Tashkin, Robert Elashoff, Philip J. Clements, Jonathan Goldin, Michael D. Roth, Daniel ... -
PEXIVAS Trial
この論文のまとめ 一言で言うと：重症の臓器障害のある顕微鏡的多発血管炎（MPA）・多発血管炎性肉芽腫症（GPA）に対して、血漿交換（PE）は追加しても大きな効果はなか...
